Stopped: PI left CCF
Individuals with cancer causing an intestinal or stomach obstruction often require gastric drainage to prevent symptoms of nausea, vomiting, and to prevent aspiration. This is often achieved by a nasogastric (NG) tube, although prolonged NG tube use can lead to unwanted side effects like ulcers, bleeding, and they are generally uncomfortable. Gastric drainage through the use of a percutaneously placed endoscopic gastrostomy (PEG) tube has been used in people with cancer since the 1980s. This allows relief of symptoms of malignant bowel obstruction though venting of stomach contents. Decompressive PEG tubes are routinely used in individuals with malignant obstruction, although these tubes tend to get clogged from food blocking the tube. The AspireAssist is a weight loss device that allows participants to remove a large amount of the food in their stomachs after each meal to help them to lose weight via an aspiration device attached to the abdominal portion of the tube which allows instillation of water into the stomach, followed by aspiration of the gastric contents into a receptacle or the toilet. The device is placed endoscopically in an identical fashion to a standard PEG tube. Although most commonly used for weight loss, the device is FDA cleared to be used as a venting tube as well. The purpose of this study is to determine if the AspireAssist provides an improved quality of life when compared with a standard venting gastrostomy tube for participants with malignant bowel obstructions.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of tube related complications per day
Timeframe: at 30 days
Patient satisfaction and ease of use survey scores
Timeframe: At baseline
Patient satisfaction and ease of use survey scores
Timeframe: At 7 days from the date of tube placement
Patient satisfaction and ease of use survey scores
Timeframe: At 30 days from the date of tube placement
Quality of life as measured by Edmonton Symptom Assessment System (ESAS)
Timeframe: At baseline
Quality of life as measured by Edmonton Symptom Assessment System (ESAS)
Timeframe: At 7 days from the date of tube placement
Quality of life as measured by Edmonton Symptom Assessment System (ESAS)
Timeframe: At 30 days from the date of tube placement